Scientists at Stanford Medicine have reported a breakthrough that could change how knee damage and arthritis are treated. In animal studies, an injectable anti-aging therapy regrew knee cartilage that normally wears away with age. It also prevented arthritis from developing after injuries similar to ACL tears. Instead of masking pain, the treatment directly targets the biological cause of cartilage loss.
The work is led by researchers at Stanford Medicine, including Helen Blau, a professor of microbiology and immunology, and Nidhi Bhutani, an associate professor of orthopaedic surgery. Their findings were published in the journal Science and involved collaboration with scientists from the Sanford Burnham Prebys Medical Discovery Institute.
In older mice, knee cartilage naturally becomes thinner and less functional. After receiving injections that block an age-related protein, the mice showed thickened cartilage across the joint surface. The regenerated tissue was healthy hyaline cartilage, the smooth type needed for normal joint movement.
The results were equally striking in injured mice. Animals with knee injuries similar to ACL tears usually develop arthritis within weeks. Mice treated with the injections twice a week for four weeks were far less likely to develop arthritis. They also moved more normally and placed more weight on the injured leg compared to untreated animals.
How the Treatment Works
The therapy targets a protein called 15-PGDH, which increases as the body ages. This protein is known as a gerozyme because it drives age-related tissue decline. 15-PGDH breaks down prostaglandin E2, a molecule that supports tissue repair.
By blocking 15-PGDH, prostaglandin E2 levels rise slightly and remain within normal biological ranges. This shift allows cartilage cells, called chondrocytes, to change how their genes behave. Instead of breaking down cartilage and fueling inflammation, these cells return to a more youthful state and begin producing healthy articular cartilage.
Importantly, this regeneration does not rely on stem cells. Existing cartilage cells are reprogrammed to repair the tissue themselves, which surprised the researchers and represents a new model for adult tissue regeneration.
To test whether the same process could apply to people, the scientists treated human knee cartilage collected during joint replacement surgeries. Within one week, the treated tissue showed reduced cartilage breakdown and began forming new, functional articular cartilage. These findings suggest that damaged human knees may also respond to the therapy.
If confirmed in clinical trials, this approach could one day restore cartilage lost to aging or arthritis and reduce the need for knee or hip replacement surgeries.
Researchers describe the results as dramatic and beyond what has been seen with any previous drug or intervention. They emphasize that this is the first treatment shown to directly reverse cartilage loss rather than simply manage symptoms. The discovery also challenges long-held beliefs that adult cartilage cannot regenerate in a meaningful way.
An oral version of the same 15-PGDH inhibitor is already in Phase 1 clinical trials for age-related muscle weakness and has been shown to be safe and biologically active in healthy volunteers. The researchers hope similar trials focused on cartilage regeneration will begin soon.
While human availability is not immediate, the progress suggests that localized injections or pills to regrow knee cartilage could become a realistic option in the coming years, offering hope to millions suffering from joint pain and arthritis.
